Clinical Outcomes by Age in Men With Hormone Refractory Prostate Cancer: A Pooled Analysis of 8 Cancer and Leukemia Group B (CALGB) Studies-Reference-Cited by-同舟云学术

Clinical Outcomes by Age in Men With Hormone Refractory Prostate Cancer: A Pooled Analysis of 8 Cancer and Leukemia Group B (CALGB) Studies

Author:

Halabi Susan¹²,Vogelzang Nicholas J.³,Ou San-San²,Kelly Wm. Kevin⁴,Small Eric J.⁵

Affiliation:

1. Department of Biostatistics and Bioinformatics, Durham, North Carolina

2. Cancer and Leukemia Group B Statistical Center, Durham, North Carolina

3. Nevada Cancer Institute and University of Nevada School of Medicine, Las Vegas, Nevada

4. Yale University School of Medicine, New Haven, Connecticut

5. Urologic Oncology Program, University of California at San Francisco, San Francisco, California

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference20 articles.

1. Cancer statistics, 2005;Jemal;Cancer J Clin,2005

2. SEER Cancer Statistics Review 1973–1998;Ries,2000

5. The use of bevacizumab (B) and docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC);Picus;Proc Am Soc Clin Oncol,2003

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献